Alvaro Alvarez Lopez

Alvaro Alvarez Lopez

Auto-generated profile, based on publicly available information

Alvaro Alvarez Lopez

University of Extremadura

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Rafael Molina-LuqueRafael Molina-Luque
Rafael Molina-Luque
Manuel Romero-SaldañaManuel Romero-Saldaña
Manuel Romero-Saldaña
CÁCarlos Álvarez-Fernández
Carlos Álvarez-Fernández
Miquel Bennasar-VenyMiquel Bennasar-Veny
Miquel Bennasar-Veny
ÁÁÁlvaro Álvarez-López
Álvaro Álvarez-López
Guillermo Molina-RecioGuillermo Molina-Recio
Guillermo Molina-Recio
Background: Many methods for measuring body fat have been developed, but applications in clinical settings are limited. For this reason, researchers have tried to identify different formulas for its estimation but most of are hard to incorporate into daily work due to the variability in population and difficulty of use. The aim of this study was to develop and validate a new equation for the simplified estimation of body fat using the Clínica Universidad de Navarra – Body Adiposity Estimator (CUN-BAE) as a reference. Methods: This research was conducted in two phases. In the first, the new body fat estimation equation was developed. The developed equation was validated in the second phase. Pearson’s linear correlation, raw and adjusted linear regressions, the intraclass correlation coefficient, and Bland–Altman graphs were used. Results: The variables that best adjusted the body fat percentage were age, sex, and the Napierian logarithm of Body Mass Index (LnBMI), forming the Equation Córdoba for Estimation of Body Fat (ECORE-BF) model. In its validation, the model presented correlation values of 0.994, an intraclass correlation coefficient of 0.960, with the Bland–Altman graph indicating means differences of 1.82 with respect to the estimation with the CUN-BAE. Nevertheless, although the aim was to simplify the CUN-BAE, the main limitation of this study is that a gold standard, such as air displacement plethysmography (ADP) or dual-energy X-ray absorptiometry (DXA), was not used. Conclusions: The proposed equation (ECORE-BF) simplified the CUN-BAE and provided a precise method, respecting the principle of parsimony, for the calculation of body fat.

23 December 2024 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
ICIsis Cerezo
Isis Cerezo
BCBárbara Cancho Castellano
Bárbara Cancho Castellano
JSJorge Alberto Rodriguez Sabillon
Jorge Alberto Rodriguez Sabillon
JSJorge Alberto Rodríguez Sabillón
Jorge Alberto Rodríguez Sabillón
ALAlvaro Alvarez Lopez
Alvaro Alvarez Lopez
NRNicolás Roberto Robles
Nicolás Roberto Robles
Aims: Serum creatinine and albuminuria are the core of most CKD prediction and progression risk models. Several biomarkers have been introduced to improve these results such as beta‐2‐microglobulin (B2M) and cystatin C (CysC). Nevertheless, few clinical comparisons of these biomarkers are available. We have compared serum B2M levels with albuminuria, CysC levels, and the CKD‐EPI GFR equations.Designs and Methods: A sample of 434 patients were studied: 234 males and 200 females, the mean age was 58.3 ± 15.0 years, and 33.4% have diabetes mellitus. In all patients, plasma B2M, CysC, creatinine, and urinary albumin excretion were analyzed. EGFR was calculated using CKD‐EPI equations for creatinine, CysC, and creatinine‐CysC. The risk of death and CKD progression was evaluated using ROC curves and Cox proportional hazards survivorship models.Results: For mortality, the highest area under the curve (AUC) was for CysC (0.775, 0.676–0.875). The lowest sensitivity was shown by eGFR (creatinine) (0.298, 0.195–0.401, p < 0.001), eGFR (CysC) (0.216, 0.118–0.314, p < 0.001), and eGFR (creatinine + CysS) (0.218, 0.124–0.312, p < 0.001). For progression to advanced CKD, the highest AUC was for CysC (0.908, 0.862–0.954). The lowest sensitivity was shown by eGFR (creatinine) (0.184, 0.106–0.261, p < 0.001), eGFR (CysC) (0.095, 0.048–0.14, p < 0.001), and eGFR (creatinine+ CysC) (0.087, 0.040–0.134, p < 0.001). CysC, after age, was the second‐best marker of life risk. Contrariwise, for CKD progression, CysC, and albuminuria were the best markers.Conclusions: The best biomarker of mortality and risk of progression to CKD was CysC. Albuminuria and B2M were the next best options to be used. The lowest sensitivity was shown by estimated eGFR.

10 October 2025 in European Journal of Internal Medicine
Verified
Journal Article
Open access
LGLaura González-Rodríguez
Laura González-Rodríguez
MAManuel Martí Antonio
Manuel Martí Antonio
SMSonia Mota-Zamorano
Sonia Mota-Zamorano
CCCelia Chicharro
Celia Chicharro
BCBárbara Cancho Castellano
Bárbara Cancho Castellano
Guillermo GervasiniGuillermo Gervasini
Guillermo Gervasini
Cardiovascular (CV) complications are the leading cause of death in patients with chronic kidney disease (CKD). Endothelin-1 (ET-1), a potent vasoconstrictor involved in both renal and vascular dysfunction, may represent a promising biomarker for the disease. ET-1 plasma levels were quantified in 692 Spanish CKD patients (stages 1-5) and used to stratify individuals into three clusters (cluster 3 meaning highest concentrations). Associations with CKD progression, CVE, and all-cause mortality were assessed over a mean follow-up of 48.6 ± 27.4 months using linear mixed-effects models and Cox regression analyses adjusted for conventional risk factors. ET-1 levels increased with CKD severity (mean±SD: 1.65 ± 0.71 pg/mL for stages 1-2; 1.82 ± 0.71 pg/mL for stage 3; 2.39 ± 1.08 pg/mL for stages 4-5; p < 0.001). Higher ET-1 levels were independently associated with accelerated eGFR decline over 3 years (β = -12.64, p < 0.001 for cluster 2; and β = -11.71, p = 0.034 for cluster 3). Sixty-nine CVE (10.1 %) were recorded. Participants with higher ET-1 levels had significantly lower CV event-free survival [HR = 2.24 (1.12-4.45), p = 0.022, and HR = 2.50 (1.09-5.73), p = 0.03] for clusters 2 and 3, respectively. ET-1 also predicted all-cause mortality (p < 0.001) although the association lost significance after adjusting for age. Random forest models for CV risk and all-cause mortality including the ET-1 cluster produced C-indices of 0.835 and 0.837, respectively. Elevated ET-1 levels are independently associated with both CKD progression and CV complications. ET-1 may serve as a dual biomarker for renal deterioration and CV risk, potentially improving clinical stratification in CKD management.

21 February 2024 in Medicina Clinica
Verified
Journal Article
Open access
BCBárbara Cancho Castellano
Bárbara Cancho Castellano
ALAlvaro Alvarez Lopez
Alvaro Alvarez Lopez
JVJulian Valladares
Julian Valladares
JSJorge Alberto Rodríguez Sabillón
Jorge Alberto Rodríguez Sabillón
JGJuan Lopez Gomez
Juan Lopez Gomez
NRNicolás Roberto Robles
Nicolás Roberto Robles
Objectives: Cystatin C is increasingly used as a marker of renal function as a complement to serum creatinine and glomerular filtration rate (GFR). We have assessed its efficacy as a predictor of mortality in a group of patients with increased cystatin C but GFR > 60 mL/min. Design and methods: We included 608 patients, 65.9% male, 34.6% had diabetes mellitus. The mean age was 58.5 +/- 14.5 years and a mean GFR of 64.1 +/- 33.5 mL/min. Patients were divided into 3 groups: CONTROL (normal cystatin C and GFR > 60 mL/min, age 53.3 +/- 12.8 years, GFR 96.6 +/- 22.4 mL/min,n = 193), INCREASED CYSTATIN (cystatin C >1.03 mg/l and GFR >60 mL/min, age 58.9 +/- 13,1 years, GFR 72.2 +/- 10.4 mL/min, n = 40) and CKD (chronic kidney disease, increased cystatin C and GFR < 60 mL/min, age 61.4 +/- 14.8 years, GFR 36.0 +/- 12.7 mL/min, n = 160). The relationship with overall mortality was analyzed using the KaplanMeier method. Results: Mean cystatin C was 0.75 +/- 0.13 versus 1.79 +/- 0.54 in CKD group and 1.14 +/- 0.14 mg/l, p < 0.001). In CONTROL group survival was 93.9% at 5 y, compared to 78.8% in the ERC group and 82.3% in the INCREASED CYSTATIN group (p < 0.001) Five-year survival before renal replacement therapy was also different for the ERC group (73%, p < 0.001 Log Rank) but not between the other two groups (CONTROL 99.0%, INCREASED CYSTATIN 94.3% p = 0.08). Conclusions: Increased plasmatic levels of cystatin C in patients with GFR > 60 mL/min was a predictor of increased mortality but not of progression to end-stage renal failure. These results confirm the interest of routinely measuring cystatin C. (c) 2024 The Author(s). Published by Elsevier Espania, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

31 May 2025 in Nefrología (English Edition)
Verified
Journal Article
Open access
BEBeatriz Escamilla-Cabrera
Beatriz Escamilla-Cabrera
MMMarco Montomoli
Marco Montomoli
MKMaria Kislikova
Maria Kislikova
VEVerónica de la Espada
Verónica de la Espada
AOAlazne Olarte-García
Alazne Olarte-García
PBPedro Barrera Baena
Pedro Barrera Baena
Chronic kidney disease (CKD) is a prevalent condition that requires reliable tools to predict its progression to end-stage renal disease (ESRD). The KFRE equation, internationally validated, allows for estimating the risk of progression at 2 and 5 years. However, it has not been validated in the Spanish population. This study aims to evaluate the predictive capacity of the KFRE in a cohort of Spanish patients. This is a multicenter, observational, and retrospective study conducted in patients with an estimated glomerular filtration rate (eGFR)<30ml/min who were followed in nephrology clinics between January 2016 and 2021. A total of 602 patients with clinical and demographic data were included. The predictive capacity of the KFRE, in its 4-variable and 8-variable versions, was evaluated using Cox regression analysis and ROC curves. Of the 602 patients included, 60% were male. Diabetes was the main etiology. Among the patients who started renal replacement therapy (RRT), 37% did so within two years, and 70% began with hemodialysis. Patients who initiated RRT (50.6%) were younger, had a lower eGFR, and exhibited higher baseline albuminuria. The 4-variable KFRE equation showed an AUC of 0.7639 (95% CI: 0.71-0.81) and demonstrated superior accuracy compared to the 8-variable model. The KFRE equation, particularly in its 4-variable version, proves to be useful in predicting the progression to ESRD in the Spanish population. However, recalibration is necessary to improve its accuracy in this context.

15 March 2023 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
NRNicolás Roberto Robles
Nicolás Roberto Robles
AAAlvaro Alvarez
Alvaro Alvarez
FFFrancesco Fici
Francesco Fici